行情

CLDX

CLDX

塞德斯医疗
NASDAQ

实时行情|Nasdaq Last Sale

1.650
+0.040
+2.48%
盘后: 1.650 0 0.00% 16:05 04/02 EDT
开盘
1.560
昨收
1.610
最高
1.870
最低
1.560
成交量
35.20万
成交额
--
52周最高
5.47
52周最低
1.500
市值
2,899.82万
市盈率(TTM)
-0.4549
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CLDX价格均价为12.00,最高价位16.00,最低价为8.00。

EPS

CLDX 新闻

更多
  • Celldex EPS beats by $0.29, beats on revenue
  • seekingalpha · 6天前
  • Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2019 Results
  • GlobeNewswire · 6天前
  • Celldex Therapeutics Reports $1.7M Milestone Payment From Rockefeller University Related To Collaboration On HIV Antibody Program
  • Benzinga · 03/03 13:25
  • Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University Related to Collaboration on HIV Antibody Program
  • GlobeNewswire · 03/03 13:01

所属板块

生物技术和医学研究
+2.93%
制药与医学研究
+2.57%

热门股票

代码
价格
涨跌幅

CLDX 简况

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.
展开

微牛提供Celldex Therapeutics, Inc.(NASDAQ-CLDX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CLDX股票新闻,以帮助您做出投资决策。